Literature DB >> 2210307

[Treatment of primary cancer of the fallopian tube].

B Pakisch1, J Poschauko, G Stücklschweiger, E Poier, M Lahousen, H Pickel, P Kohek, P Klug, A Hackl.   

Abstract

33 patients treated since 1970 at the Medical School of the University of Graz, were classified using the FIGO system for ovarian carcinoma, fourteen were in stage I, 8 stage II, 8 stage III and 3 stage IV. In 17 patients, surgery consisted of total abdominal or vaginal hysterectomy with bilateral salpingo-oophorectomy; 12 patients underwent additional pelvic +/- paraaortic lymph node extirpation and in 4 the tumour excision was incomplete. Treatment in 6 patients was surgery alone (2/stage I, 4 with advanced disease) (Group A). Adjuvant radiotherapy was performed in 14 patients (Group B); the remaining patients were treated with single (2/13) or multiple agent chemotherapy (11/13) (Group C). The 3-year survival rate was 55% for stage I, 42% for stage II; 10/11 of the stage III/IV patients died within 26 months. The 4-year actuarial survival rate for group B was 68%, for group C 11%. There was no difference between the short-time results of stage II tumours when comparing radiotherapy against chemotherapy. The tumour progression rate was 60%, indicating the need for radical surgery as well as for more aggressive adjuvant treatment. Surgery alone is recommended for stage I disease confined to the mucosa. More advanced disease (extension to the serosa, stage Ic, stage II) requires whole abdominal irradiation with a boost to the pelvic lymph nodes. For stage III/IV tumours a multi-modality treatment is recommended. Chemotherapy (cis-platinum, cyclophosphamide) for recurrent disease resulted in remission in some cases.

Entities:  

Mesh:

Year:  1990        PMID: 2210307     DOI: 10.1055/s-2008-1026307

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  5 in total

1.  Radical lymphadenectomy in the primary carcinoma of the fallopian tube.

Authors:  M Klein; A Rosen; M Lahousen; A Graf; N Vavra; A Beck
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

2.  Evaluation of adjuvant therapy after surgery for primary carcinoma of the fallopian tube.

Authors:  M Klein; A Rosen; M Lahousen; A Graf; N Vavra; B Pakisch; J Poschauko; A Beck; H Kucera
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

3.  Primary fallopian tube carcinoma--a retrospective survey of 51 cases. Austrian Cooperative Study Group for Fallopian Tube Carcinoma.

Authors:  M Klein; A Rosen; A Graf; M Lahousen; H Kucera; B Pakisch; N Vavra; A Beck
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

4.  A comparative analysis of management and prognosis in stage I and II fallopian tube carcinoma and epithelial ovarian cancer.

Authors:  A C Rosen; P Sevelda; M Klein; A H Graf; M Lahousen; A Reiner; L Auerbach; N Vavra; H R Rosen
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

5.  Primary carcinoma of the fallopian tube--a retrospective analysis of 115 patients. Austrian Cooperative Study Group for Fallopian Tube Carcinoma.

Authors:  A Rosen; M Klein; M Lahousen; A H Graf; A Rainer; N Vavra
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.